Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615660 | 0.86 | MMP1 (0.35) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL1615661 | 0.82 | MMP1 (0.42) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL18426999 | 0.82 | MMP1 (0.33) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL21145497 | 0.80 | MMP1 (0.41) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL4302310 | 0.80 | MMP1 (0.38) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL28308289 | 0.79 | MMP1 (0.31) | MMP1MMP3MMP8ANPEP | |
| SCHEMBL27667273 | 0.77 | MMP1 (0.33) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL329844 | 0.76 | MMP1 (0.45) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL8505349 | 0.76 | TSHR (0.36) | MMP1MMP3MMP8ANPEPCA12 | |
| SCHEMBL2974387 | 0.76 | MMP1 (0.45) | MMP1MMP3MMP8ANPEPCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5699 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291244-B1 | CELL-PENETRATING PEPTIDE CONJUGATES AND METHODS OF THEIR USE | UNIV OXFORD INNOVATION LTD (GB) | 2025-12-10 | — | — | EP | claimed |
| EP-3250591-B1 | HUMAN ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN | REGENERON PHARMA (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250332270-A1 | Targeting Skin-Related Conditions Using Bottlebrush Polymer-Conjugated Oligonucleotides | UNIV NORTHEASTERN (US) | 2025-10-30 | — | — | US | claimed |
| EP-4610278-A2 | TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERS | Sapreme Technologies B.V. (NL) | 2025-09-03 | — | — | EP | claimed |
| US-20250250564-A2 | COMPOSITIONS COMPRISING THERAPEUTIC NUCLEIC ACID AND SAPONIN FOR THE TREATMENT OF MUSCLE-WASTING DISORDERS | SAPREME TECH BV (NL) | 2025-08-07 | — | — | US | claimed |
| EP-4452331-B1 | TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERS | SAPREME TECH BV (NL) | 2025-08-06 | — | — | EP | claimed |
| US-20250163418-A1 | Brush polymer-oligonucleotide conjugates for the treatment of muscular dystrophy | UNIV NORTHEASTERN (US) | 2025-05-22 | — | — | US | claimed |
| WO-2025085618-A1 | METHODS FOR APPENDING ADAPTORS ONTO POLYNUCLEOTIDES | ILLUMINA, INC. (US) | 2025-04-24 | — | — | WO | claimed |
| EP-3660154-B1 | ANTISENSE NUCLEIC ACID FOR USE IN TREATING DUCHENNE MUSCULAR DYSTROPHY | NIPPON SHINYAKU CO LTD (JP) | 2025-04-16 | — | — | EP | claimed |
| US-20250082759-A1 | COMPOSITIONS COMPRISING THERAPEUTIC NUCLEIC ACID AND TARGETED SAPONIN FOR THE TREATMENT OF MUSCLE-WASTING DISORDERS | SAPREME TECHNOLOGIES B.V. (NL) | 2025-03-13 | — | — | US | claimed |
| US-20060147952-A1 | 2'-O-methyl-phosphorothioate oligoribonucleotide modification; peptide nucleic acids, locked nucleic acids, and/or morpholino phosphorodiamidate oligonucleotides; splicing to skip hybridization | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2006-07-06 | — | — | US | claimed |
| US-20060099616-A1 | 2'-O-methyl-phosphorothioate oligoribonucleotide modification; peptide nucleic acids, locked nucleic acids, and/or morpholino phosphorodiamidate oligonucleotides; splicing to skip hybridization | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2006-05-11 | — | — | US | claimed |
| WO-2006002540-A1 | OLIGONUCLEOTIDES TARGETING PRION DISEASES AND USES | REPLICOR INC. (CA) | 2006-01-12 | — | — | WO | claimed |
| EP-1606407-A2 | MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE | Academisch Ziekenhuis Leiden (NL) | 2005-12-21 | — | — | EP | claimed |
| US-20050233455-A1 | Acyclic linker-containing oligonucleotides and uses thereof | DAMHA MASAD J | 2005-10-20 | — | — | US | claimed |
| WO-2004083432-A1 | MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2004-09-30 | — | — | WO | claimed |
| WO-2004083446-A2 | MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2004-09-30 | — | — | WO | claimed |
| EP-1440079-A1 | ACYCLIC LINKER-CONTAINING OLIGONUCLEOTIDES AND USES THEREOF | McGILL UNIVERSITY (CA) | 2004-07-28 | — | — | EP | claimed |
| US-20030220249-A1 | Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation, and methods of use thereof | DISCOVERY GENOMICS, INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003037909-A1 | ACYCLIC LINKER-CONTAINING OLIGONUCLEOTIDES AND USES THEREOF | MCGILL UNIVERSITY (CA) | 2003-05-08 | — | — | WO | claimed |